利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.014 秒)

    Acyl transfer with stabilized transition complex using catalyst with catalytic imidazole (e.g. histidine) function
    2.
    发明授权
    Acyl transfer with stabilized transition complex using catalyst with catalytic imidazole (e.g. histidine) function 有权
    使用具有催化咪唑（例如组氨酸）的催化剂的具有稳定的过渡配合物的酰基转移

    公开(公告)号：US06171819B2

    公开(公告)日：2001-01-09

    申请号：US09180670

    申请日：1998-12-02

    申请人： Per Ahlberg ,  Lars Baltzer

    发明人： Per Ahlberg ,  Lars Baltzer

    IPC分类号： C12P2106

    CPC分类号： C07K1/10 ,  C07K1/04

    摘要： The invention relates to a method of performing a chemical reaction between a reagent and a substrate, involving an acyl transfer mechanism, in the presence of an imidazole-based catalyst capable of forming a transition complex with the substrate. The catalytic imidazole function is provided by a chemical structure element comprising an optionally substituted imidazolyl group flanked on one or both sides by a group or groups capable of stabilizing the transition complex by molecular interaction with the acyl group. The invention also relates to such a designed chemical structure element, a method of producing it by recombinant DNA techniques and a vector therefor.

    摘要翻译： 本发明涉及在能够与底物形成转移复合物的咪唑类催化剂的存在下，在试剂和底物之间进行包括酰基转移机理的化学反应的方法。 催化咪唑功能由化学结构元件提供，该化学结构元件包括在一侧或两侧侧面具有任选取代的咪唑基，所述基团可以通过与酰基的分子相互作用而能够稳定转变复合物的基团或基团。 本发明还涉及这种设计的化学结构元件，通过重组DNA技术生产它的方法及其载体。

    NOVEL DIAGNOSTIC SENSOR FOR RAPID AND REPRODUCIBLE RO52 PROTEIN DOMAIN DETECTION
    3.
    发明申请
    NOVEL DIAGNOSTIC SENSOR FOR RAPID AND REPRODUCIBLE RO52 PROTEIN DOMAIN DETECTION 审中-公开
    用于快速和可重复RO52蛋白质区域检测的新型诊断传感器

    公开(公告)号：US20100304398A1

    公开(公告)日：2010-12-02

    申请号：US12532195

    申请日：2008-03-21

    申请人： Ola Winqvist ,  Marie Wahren-Herlenius ,  Lars Baltzer

    发明人： Ola Winqvist ,  Marie Wahren-Herlenius ,  Lars Baltzer

    IPC分类号： G01N33/53 ,  G01N33/566

    CPC分类号： G01N33/689 ,  G01N2800/325

    摘要： The present invention relates to the use of specific synthetic sensor molecules for the discrimination of proteins and protein domains involved in autoimmunity. More specifically, in one embodiment, the invention relates to the detection of antibodies which bind to specific domains of the Ro52 protein. In another embodiment, the invention relates to the use of specific synthetic sensor molecules to identify domains of the Ro52 protein with different antibody specificities. The invention also includes a method for assessing the risk that a fetus will develop congenital heart block. The invention enables the evaluation and differential diagnosis of a range of autoimmune disorders, allowing appropriate treatment or more generally medical intervention decisions to be made.

    摘要翻译： 本发明涉及特定的合成传感器分子用于鉴定参与自身免疫的蛋白质和蛋白质结构域的用途。 更具体地，在一个实施方案中，本发明涉及检测结合Ro52蛋白的特异性结构域的抗体。 在另一个实施方案中，本发明涉及使用特定的合成传感器分子来鉴定具有不同抗体特异性的Ro52蛋白的结构域。 本发明还包括评估胎儿将发展先天性心脏阻塞的风险的方法。 本发明能够对一系列自身免疫性疾病进行评估和鉴别诊断，从而允许进行适当的治疗或更一般的医疗干预决定。

    Binder for C-reactive protein
    5.
    发明授权
    Binder for C-reactive protein 失效
    C反应蛋白的粘合剂

    公开(公告)号：US08436138B2

    公开(公告)日：2013-05-07

    申请号：US13218875

    申请日：2011-08-26

    申请人： Lars Baltzer

    发明人： Lars Baltzer

    IPC分类号： A61K38/00

    CPC分类号： G01N33/6893 ,  A61K38/00 ,  A61K47/544 ,  C07K1/1077 ,  C07K14/001 ,  C07K14/4737 ,  G01N2333/4737

    摘要： Isolated polypeptides comprising one or more of SEQ ID NOs 3-18, which show a specific binding for C-reactive protein (CRP). A library of isolated polypeptides comprising the polypeptides of SEQ ID NOs 3-18 is disclosed, as are compositions comprising such polypeptides.

    摘要翻译： 分离的多肽包含SEQ ID NO：3-18中的一个或多个，其显示出对C-反应蛋白（CRP）的特异性结合。 公开了包含SEQ ID NO：3-18的多肽的分离的多肽的文库，以及包含这些多肽的组合物。

    Binder for C-reactive protein
    6.
    发明授权
    Binder for C-reactive protein 失效
    C反应蛋白的粘合剂

    公开(公告)号：US08017347B2

    公开(公告)日：2011-09-13

    申请号：US12225386

    申请日：2007-04-10

    申请人： Lars Baltzer

    发明人： Lars Baltzer

    IPC分类号： G01N33/53 ,  C12P21/06 ,  A61K38/00 ,  C07K1/00

    CPC分类号： G01N33/6893 ,  A61K38/00 ,  A61K47/544 ,  C07K1/1077 ,  C07K14/001 ,  C07K14/4737 ,  G01N2333/4737

    摘要： A polypeptide dimer is provided wherein both protomers have a sequence according to SEQ ID NO: 1 and at least one phosphocholine derivative is attached to the polypeptide. The polypeptide shows a specific binding for C-reactive protein (CRP). The utilization of the polypeptide in assays for determining the concentration of CRP is described. The purification of CRP, and compositions comprising the CRP also are provided.

    摘要翻译： 提供多肽二聚体，其中两个protomers都具有根据SEQ ID NO：1的序列，并且至少一个磷酸胆碱衍生物连接到多肽上。 多肽显示出对C-反应蛋白（CRP）的特异性结合。 描述了用于确定CRP浓度的测定中多肽的利用。 还提供了CRP的纯化和包含CRP的组合物。

    Computer system for determining a drug dosage
    8.
    发明申请
    Computer system for determining a drug dosage 审中-公开
    用于确定药物剂量的计算机系统

    公开(公告)号：US20070067148A1

    公开(公告)日：2007-03-22

    申请号：US10595491

    申请日：2004-10-21

    申请人： Peter Fritzson ,  Lars Baltzer

    发明人： Peter Fritzson ,  Lars Baltzer

    IPC分类号： G06G7/48

    CPC分类号： G06F19/326 ,  G06F19/3456

    摘要： An apparatus for determining a drug dosage is disclosed comprising: an input interface for receiving data on at least one patient's biochemical profile, and data on at least one specific property of the drug; and processing means having a simulation module for simulating the effect of a certain dosage based on the received data, and an evaluation module for determining, based on a simulation on at least one dosage, a drug dosage for the at least one patient in question. A corresponding method is also disclosed. Hereby, a dosage may be personalized on the basis of the condition and state of each patient, leading to a more effective dosage. This leads to a better and less hazardous treatment of the patient, as well as decreased health related costs in the society. Further, the strain on the environment could be reduced.

    摘要翻译： 公开了一种用于确定药物剂量的装置，包括：输入界面，用于接收关于至少一个患者生物化学特征的数据，以及关于所述药物的至少一种具体特性的数据; 以及具有模拟模块的处理装置，用于模拟基于接收到的数据的某一剂量的效果;以及评估模块，用于基于至少一个剂量的模拟来确定所述至少一个患者的药物剂量。 还公开了相应的方法。 因此，可以基于每个患者的状况和状态来个体化剂量，导致更有效的剂量。 这导致对患者的更好和更少的危害性治疗，以及社会中与健康有关的成本降低。 此外，可以减少对环境的压力。

    DETECTION METHOD AND DEVICE BASED ON NANOPARTICLE AGGREGATION
    10.
    发明申请
    DETECTION METHOD AND DEVICE BASED ON NANOPARTICLE AGGREGATION 审中-公开
    基于纳米尺度聚集的检测方法和装置

    公开(公告)号：US20120202218A1

    公开(公告)日：2012-08-09

    申请号：US13063610

    申请日：2009-09-14

    申请人： Bo Liedberg ,  Daniel Aili ,  Lars Baltzer ,  Karin Enander ,  Johan Rydberg

    发明人： Bo Liedberg ,  Daniel Aili ,  Lars Baltzer ,  Karin Enander ,  Johan Rydberg

    IPC分类号： G01N33/573 ,  C40B60/12 ,  G01N33/566 ,  B82Y15/00

    CPC分类号： G01N33/54313 ,  B82Y15/00 ,  B82Y30/00 ,  G01N33/54306

    摘要： A method for determining the presence of a compound in a liquid solution, by admixing the liquid solution with a plurality of nanoparticles; providing conditions effective to cause aggregation of the nanoparticles in the liquid solution in the absence of said compound in the liquid solution; and observing a detectable signal reflecting the amount of aggregation of nanoparticles in the liquid solution, wherein the presence of the compound in the liquid solution results in a detectable signal reflecting a reduced amount of aggregation of nanoparticles in the liquid solution, in comparison to the amount of aggregation of nanoparticles obtained in the liquid solution in the absence of the compound therein. A nanoparticle, a composition, a kit and a for multi-well plate for use in the method are also disclosed. In some embodiments the association is cation-, anion and/or PH induced e.g. by using helix-loop-helix polypeptides as first and second molecules attached to the nanoparticles. The first molecules are directed to the target compound, the second molecules allow for aggregation of the nanoparticles.

    摘要翻译： 一种通过将液体溶液与多种纳米颗粒混合来确定化合物在液体溶液中的存在的方法; 提供在液体溶液中不存在所述化合物的情况下有效引起纳米颗粒在液体溶液中的聚集的条件; 并观察反映液体溶液中纳米颗粒聚集量的可检测信号，其中化合物在液体溶液中的存在导致反映在液体溶液中纳米颗粒聚集量减少的可检测信号， 在不存在化合物的情况下在液体溶液中获得的纳米颗粒的聚集。 还公开了用于该方法的纳米颗粒，组合物，试剂盒和用于多孔板的试剂盒。 在一些实施方案中，所述缔合是阳离子，阴离子和/或PH诱导的。 通过使用螺旋 - 环 - 螺旋多肽作为连接到纳米颗粒的第一和第二分子。 第一分子被引导到目标化合物，第二分子允许纳米颗粒的聚集。